title: [Anti-human IgG-dextran-adriamycin conjugate for immunotargeting of S180 sarcoma: effects on the tumor weight and survival time of the tumor-bearing mice].
abstract: OBJECTIVE
  To prepare anti-human IgG-dextran-adriamycin conjugate for immunotargeting of S180 sarcoma and assess its effects on the tumor weight and survival time of the tumor-bearing mice.
  
  
  METHODS
  Anti-human IgG-dextran- adriamycin was synthesized by conjugating dextran and adriamycin with anti-human IgG. The immunoactivity of anti-human IgG-dextran-adriamycin was measured by enzyme-linked immunosorbent assay (ELISA), and the cytotoxicity of anti-human IgG, adriamycin, and the IgG-dextran-adriamycin conjugate against the tumor cells in vitro was evaluated using MTT assay. In mice bearing S180 sarcoma, the agents were tested for their effects against tumor cell growth and the survival time of mice.
  
  
  RESULTS
  The molar ratio of anti-mouse IgG, dextran, and adriamycin was 1:2.5:38 in the conjugate. The conjugates were shown to retain the immunoactivity of anti-human IgG, and possessed cytotoxicity to S180 cells in vitro. Administration of the conjugate and intratumor injection of human IgG resulted in a tumor suppression rate of 17.72%in mice bearing S180 sarcoma, but did not prolong the survival time of the mice.
  
  
  CONCLUSIONS
  The anti-human IgG-dextran-adriamycin conjugate shows targeted antitumor effect against S180 sarcoma in mice.
authors.affiliation: Oncology Center, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. zhangjing_426@Yahoo.com.cn
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Luo
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zhou
authors.forename: Ji-ren
authors.initials: JR
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D003911:Dextrans / Q000008:administration & dosage / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000494:pharmacology*; D000922:Immunotoxins / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D003911:Dextrans; D007074:Immunoglobulin G; D000922:Immunotoxins; C048844:anti-IgG; C056869:immunoglobulin G-dextran conjugate; D004317:Doxorubicin